pancreatitis caused by semaglutide Acute due to different regimens: An updated meta-analysis Wegovy and The Pancreas

Informed consent matters The legal concept at the heart of these lawsuits is informed consent

In that study, tirzepatide was associated with greater average weight loss: People taking the highest dose lost an average of 20.2% of their body weight, compared with 13.7% for those taking semaglutide

Some individuals may experience adverse events, including gastrointestinal issues and hypoglycemia

Co-primary endpoints encompassed the percentage alteration in body weight from baseline to week 104 and the attainment of weight loss equivalent to or greater than 5% of baseline weight at week 104

Cell Metab 27(4):740756 Drucker DJ (2020) Advances in oral peptide therapeutics